NDF Research’s Initiation of Coverage Research & Valuation Report
NDF Research has released its first research and valuation report on Anatara Lifesciences (ANR). The report valued Anatara at $2.22 base case and $5.94 optimistic case using a DCF approach, with a target price of $4.00 sitting at around the midpoint of the valuation range.
Please click on the PDF to view the report.